Literature DB >> 11055247

Alteration of virus entry mode: a neutralisation mechanism for Dengue-2 virus.

S Y Se-Thoe1, A E Ling, M M Ng.   

Abstract

Polyclonal antibodies derived from dengue virus immune sera and 3H5 monoclonal antibody showed potent neutralisation effect on dengue-2 virus in the plaque reduction neutralisation assay. This study demonstrated that antibodies present in immune human sera and 3H5 monoclonal antibody neutralised dengue-2 virus by altering the virus entry pathway into cells. In the presence of neutralising antibodies, dengue-2 virus was endocytosed by LLC-MK2 cells. The endocytosis process involved ruffling of antibody-coated virions by cellular pseudopodia and invagination of cell membrane. This mode of entry is atypical as compared to direct fusion of dengue-2 virus with cell membrane in the absence of antibody. The virions were internalised in the form of virion-antibody complexes consisting of single or clumps of virions. After 3 minutes of incubation, neutralised virions were detected in cellular vesicles, and signs of intra-endosomal penetration into cytoplasm were not evident even after a prolonged incubation of 10 minutes, suggesting that viral uncoating was compromised. Vesicle-bound virions were no longer detected after 20 minutes of incubation. In addition, no sign of viral replication was detected in cells infected with "neutralised" virions by immunofluorescence assay. This indicated that internalised virions had been degraded leading to abortive infection. In conclusion, antibodies present in 3H5 monoclonal antibody and human immune sera rendered dengue-2 virus non-infective by neutralising the viral fusion site and causing alteration of viral entry mode. Antibodies in immune sera but not 3H5 monoclonal antibody also exerted minimal inhibitory effect on virus binding and internalisation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055247     DOI: 10.1002/1096-9071(200011)62:3<364::aid-jmv9>3.0.co;2-s

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Rab 5 is required for the cellular entry of dengue and West Nile viruses.

Authors:  Manoj N Krishnan; Bindu Sukumaran; Utpal Pal; Herve Agaisse; James L Murray; Thomas W Hodge; Erol Fikrig
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

3.  In vivo mechanisms of vaccine-induced protection against HPV infection.

Authors:  Patricia M Day; Rhonda C Kines; Cynthia D Thompson; Subhashini Jagu; Richard B Roden; Douglas R Lowy; John T Schiller
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

Review 4.  The structural immunology of antibody protection against West Nile virus.

Authors:  Michael S Diamond; Theodore C Pierson; Daved H Fremont
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

5.  Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus.

Authors:  Hans-Christoph Selinka; Luise Florin; Hetal D Patel; Kirsten Freitag; Michaela Schmidtke; Vadim A Makarov; Martin Sapp
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

6.  Characterization of dengue virus entry into HepG2 cells.

Authors:  Lukkana Suksanpaisan; Tharinee Susantad; Duncan R Smith
Journal:  J Biomed Sci       Date:  2009-02-04       Impact factor: 8.410

7.  A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes.

Authors:  Bruce S Thompson; Bastiaan Moesker; Jolanda M Smit; Jan Wilschut; Michael S Diamond; Daved H Fremont
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

8.  Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI.

Authors:  Yujia Li; Cherie Kakinami; Qi Li; Baojun Yang; Hongwei Li
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.